{"generic":"Gold Sodium Thiomalate","drugs":["Gold Sodium Thiomalate","Myochrysine"],"mono":{"0":{"id":"260060-s-0","title":"Generic Names","mono":"Gold Sodium Thiomalate"},"1":{"id":"260060-s-1","title":"Dosing and Indications","sub":[{"id":"260060-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Rheumatoid arthritis:<\/b> initial, 10 mg IM 1st week, 25 mg IM 2nd week, then 25-50 mg IM weekly until response, toxicity or 1 g cumulative dose<\/li><li><b>Rheumatoid arthritis:<\/b> maintenance with continued clinical improvement, 25-50 mg IM every other week, then every third week, then every fourth week as tolerated<\/li><\/ul>"},{"id":"260060-s-1-5","title":"Pediatric Dosing","mono":"<b>Rheumatoid arthritis:<\/b> test dose 10 mg IM, then 1 mg\/kg (maximum 50 mg\/dose) IM weekly for 20 wk; maintenance, 1 mg\/kg IM (maximum 50 mg\/dose) every 2-4 weeks"},{"id":"260060-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> CrCl greater than 50 mL\/min, no dosage adjustment necessary; CrCl less than 50 mL\/min, not recommended"},{"id":"260060-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Rheumatoid arthritis<br\/>"}]},"2":{"id":"260060-s-2","title":"Black Box Warning","mono":"<b>Intramuscular (Solution)<\/b><br\/>Physicians should be familiar with the drug's toxicity and benefits before use. Patients should report promptly any symptoms suggesting toxicity. Monitor the patient and the results of laboratory work to determine the presence or absence of adverse reactions, since some of these can be severe or even fatal.<br\/>"},"3":{"id":"260060-s-3","title":"Contraindications\/Warnings","sub":[{"id":"260060-s-3-9","title":"Contraindications","mono":"<ul><li>moderate to severe renal failure<\/li><li>systemic lupus erythematosus<\/li><li>severe debilitation<\/li><li>toxicity to gold\/heavy metals<\/li><\/ul>"},{"id":"260060-s-3-10","title":"Precautions","mono":"<ul><li>allergies or hypersensitivity to other medications<\/li><li>compromised cardiovascular circulation<\/li><li>compromised cerebral circulation<\/li><li>concurrent penicillamine<\/li><li>history of blood dyscrasias<\/li><li>previous hepatic insufficiency<\/li><li>previous renal insufficiency<\/li><li>severe hypertension<\/li><li>skin rash<\/li><\/ul>"},{"id":"260060-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"260060-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"260060-s-4","title":"Drug Interactions","sub":{"1":{"id":"260060-s-4-14","title":"Major","mono":"<ul>Penicillamine (established)<\/ul>"},"2":{"id":"260060-s-4-15","title":"Moderate","mono":"<ul><li>Benazepril (probable)<\/li><li>Captopril (probable)<\/li><li>Cilazapril (probable)<\/li><li>Enalapril (probable)<\/li><li>Fosinopril (probable)<\/li><li>Lisinopril (probable)<\/li><li>Moexipril (probable)<\/li><li>Perindopril (probable)<\/li><li>Quinapril (probable)<\/li><li>Ramipril (probable)<\/li><li>Trandolapril (probable)<\/li><li>Zofenopril (probable)<\/li><\/ul>"}}},"5":{"id":"260060-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus, Rash, Skin or mucosa lesion (20%)<\/li><li><b>Gastrointestinal:<\/b>Stomatitis<\/li><li><b>Renal:<\/b>Proteinuria (10% to 15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Enterocolitis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia, Pancytopenia, Thrombocytopenia (1% to 3%)<\/li><li><b>Hepatic:<\/b>Cholestatic jaundice syndrome, Hepatotoxicity<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypogammaglobulinemia<\/li><li><b>Neurologic:<\/b>Cerebral ischemia, Encephalopathy<\/li><li><b>Renal:<\/b>Acute renal failure, Nephrotic syndrome<\/li><li><b>Respiratory:<\/b>Interstitial lung disease, Pneumonitis (less than 0.1%)<\/li><\/ul>"},"6":{"id":"260060-s-6","title":"Drug Name Info","sub":{"0":{"id":"260060-s-6-17","title":"US Trade Names","mono":"Myochrysine<br\/>"},"2":{"id":"260060-s-6-19","title":"Class","mono":"<ul><li>Antirheumatic<\/li><li>Gold Compound<\/li><\/ul>"},"3":{"id":"260060-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"260060-s-7","title":"Mechanism Of Action","mono":"Gold sodium thiomalate has an unknown mechanism of action, however, it is believed to exert a suppressive effect on the inflammation of the synovial membrane of active rheumatoid arthritis. It controls the progression of the disease and arrests further structural damage to the joints in the late stage of the illness.<br\/>"},"9":{"id":"260060-s-9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>administer by IM injection only, preferably intragluteally with patient lying down; keep patient recumbent 10 min after injection<\/li><li>do not administer if solution color exceeds pale yellow<\/li><\/ul>"},"10":{"id":"260060-s-10","title":"Monitoring","mono":"<ul><li>improved range of motion, decreased early morning stiffness and painful\/swollen joints, C-reactive protein levels, erythrocyte sedimentation rate<\/li><li>CBC with differential, platelet counts; baseline, then prior to every second injection<\/li><li>liver function<\/li><li>pulmonary function<\/li><li>skin examination<\/li><li>urinalysis; baseline, then prior to each injection<\/li><\/ul>"},"12":{"id":"260060-s-12","title":"Toxicology","sub":[{"id":"260060-s-12-31","title":"Clinical Effects","mono":"<b>GOLD DRUGS<\/b><br\/>OVERDOSE: Overdose data are limited. Overdose effects would be expected to be an extension of adverse effects seen at therapeutic doses. Ventricular tachycardia was reported after acute overdose in one case. ADVERSE EFFECTS: Common problems with therapeutic use include allergic dermatitis (12% to 55%), stomatitis, alopecia, hypersensitivity pneumonitis, drug-induced lupus, and rarely thrombocytopenia (incidence about 1%).<br\/>"},{"id":"260060-s-12-32","title":"Treatment","mono":"<b>GOLD DRUGS <\/b><br\/><ul><li>Decontamination: Metallic gold is poorly adsorbed by activated charcoal. Experience with activated charcoal following gold toxicities is limited.<\/li><li>Support:  If a toxic reaction occurs during therapeutic administration, discontinue the use of the drug.  Often, toxicity is reversible on discontinuation alone. The primary treatment for gold toxicity has been patient support during any hematologic, respiratory, and\/or gastrointestinal reactions.  Chelation has been used to reduce the amount of circulating gold, but its efficacy is unclear.  It is nearly impossible to remove all the gold from the body.<\/li><\/ul>"},{"id":"260060-s-12-33","title":"Range of Toxicity","mono":"<b>GOLD DRUGS<\/b><br\/>TOXICITY: There appears to be little correlation between total gold dose and toxicity. In a summary of 20 cases of toxicity after therapeutic use, the cumulative toxic dose was from 230 mg to 10 g of gold salt. Acute administration of intramuscular aurothioglucose 500 mg in one adult and 1000 mg in another did not cause acute toxicity. THERAPEUTIC DOSE: GOLD SODIUM THIOMALATE (ADULT) - Initial: 10 mg IM 1st week, 25 mg IM 2nd week, then 25 to 50 mg IM weekly until response, toxicity or 1 g cumulative dose. Maintenance with continued clinical improvement: 25 to 50 mg IM every other week, then every third week, then every fourth week as tolerated. GOLD SODIUM THIOMALATE (PEDIATRIC) - Test dose of 10 mg IM, then 1 mg\/kg (maximum 50 mg\/dose) IM weekly for 20 wk; maintenance, 1 mg\/kg IM (maximum 50 mg\/dose) every 2 to 4 weeks. <br\/>"}]},"13":{"id":"260060-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause rash, pruritus, or stomatitis.<\/li><li>Patient should report signs\/symptoms of aplastic anemia, or nephrotic syndrome (edema, weight gain, decreased appetite, foamy urine).<\/li><li>Instruct patient to remain recumbent for at least 10 min after injection.<\/li><\/ul>"}}}